Completed OBSERVATIONAL NCT02429518

Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis

Sponsor: Knight Therapeutics (USA) Inc

Interventions Miltefosine

Updated 10 times since 2017 Last updated: Sep 2, 2020 Started: Dec 31, 2015 Primary completion: Jun 6, 2017 Completion: Mar 6, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Mucocutaneous Leishmaniasis, this trial is completed. The trial is conducted by Knight Therapeutics (USA) Inc and has accumulated 10 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Oct 2020 — Jan 2021 [monthly]

Completed

Status: Unknown Status → Completed
Apr 2020 — Oct 2020 [monthly]

Unknown Status

Status: Recruiting → Unknown Status

▶ Show 5 earlier versions

Jun 2018 — Apr 2020 [monthly]

Recruiting
Apr 2018 — Jun 2018 [monthly]

Recruiting

Phase: NA → None
Mar 2017 — Apr 2018 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Feb 2017 — Mar 2017 [monthly]

Not Yet Recruiting NA
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting NA

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Knight Therapeutics (USA) Inc

Data source: Knight Therapeutics (USA) Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Santa Cruz, Bolivia